Literature DB >> 1699908

Reduction of the local toxicity of intraperitoneal chemotherapy; an experimental model.

R G Molloy1, B Crowley, K T Moran, M P Brady.   

Abstract

Intraperitoneal (I.P.) administration of chemotherapeutic agents, in particular, cisplatin and bleomycin is successfully used in the treatment of ovarian and gastrointestinal malignancies. Their use however, is limited by the rapid development of adhesions. The vinca alkaloid group of chemotherapeutic agents has been shown to impair the acute inflammatory reaction, which plays an important role in adhesion formation, thereby providing the rationale for addition of vindesine to an I.P. regimen containing cisplatin and bleomycin. A rat model was used to study the effects of various I.P. chemotherapeutic regimens on adhesion formation. Four groups were studied (30 rats/Group). Regimens used included Group A (Saline), Group B (Vindesine 0.1 mg/kg), Group C (Cisplatin 5 mg/kg and Bleomycin 0.2 mg/kg), and Group D (Cisplatin 5 mg/kg, Bleomycin 0.2 mg/kg and Vindesine 0.1 mg/kg). In order to grade adhesion formation, animals were sacrificed on days 2, 14 and 28, with the severity of adhesions graded on a scale of I-IV in order of increasing severity. Adhesion formation in Group A (Saline) and Group B (Vindesine) was similar. The addition of Vindesine to Group C (Cisplatin and Bleomycin) resulted in a significant reduction in adhesion formation (p less than 0.01). The results of this experimental study suggest that the local toxicity of I.P. chemotherapy may be reduced by the inclusion of a vinca alkaloid.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1699908     DOI: 10.1007/bf02937237

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  28 in total

1.  Ip chemotherapy employing a regimen of cisplatin, cytarabine, and bleomycin.

Authors:  M Markman; S Cleary; W Lucas; R Weiss; S B Howell
Journal:  Cancer Treat Rep       Date:  1986-06

2.  Long-term survival after vinblastine, bleomycin, and cisplatin treatment in patients with germ cell tumors of the ovary: an update.

Authors:  P H Willemse; J G Aalders; J Bouma; N H Mulder; R C Verschueren; E G de Vries; D T Sleijfer
Journal:  Gynecol Oncol       Date:  1987-11       Impact factor: 5.482

3.  Reduced human peritoneal plasminogen activating activity: possible mechanism of adhesion formation.

Authors:  J N Thompson; S Paterson-Brown; T Harbourne; S A Whawell; E Kalodiki; H A Dudley
Journal:  Br J Surg       Date:  1989-04       Impact factor: 6.939

4.  Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study.

Authors:  S Gundersen
Journal:  Cancer Treat Rep       Date:  1987-11

5.  Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer.

Authors:  R F Ozols; R C Young; J L Speyer; P H Sugarbaker; R Greene; J Jenkins; C E Myers
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

6.  Effects of antineoplastic agents on wound healing in mice.

Authors:  S C Cohen; H L Gabelnick; R K Johnson; A Goldin
Journal:  Surgery       Date:  1975-08       Impact factor: 3.982

7.  Phase II trial of vinblastine in previously treated patients with ovarian cancer: a Southwest Oncology Group Study.

Authors:  E A Surwit; D S Alberts; R V O'Toole; V Graham; E V Hannigan; R L Stephens; J G Boutselis
Journal:  Gynecol Oncol       Date:  1987-09       Impact factor: 5.482

8.  Local and systemic toxicity resulting from large-volume ip administration of doxorubicin in the rat.

Authors:  C L Litterst; J M Collins; M C Lowe; S T Arnold; D M Powell; A M Guarino
Journal:  Cancer Treat Rep       Date:  1982-01

9.  Complications of extensive adhesion formation after intraperitoneal chemotherapy.

Authors:  M Markman; S Cleary; S B Howell; W E Lucas
Journal:  Surg Gynecol Obstet       Date:  1986-05

10.  Palliative and adjuvant chemotherapy of metastatic renal cancer.

Authors:  J Kühböck; P Pötzi; T Madaras
Journal:  Semin Surg Oncol       Date:  1988
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.